



September 1, 2022

Harbourside CPA LLP Clearhouse LLP  
Ontario Securities Commission  
British Columbia Securities Commission  
Alberta Securities Commission  
Manitoba Securities Commission

Re: Notice of Change of Auditors

In compliance with section 4.11 of National Instrument 51-102 – Continuous Disclosure Obligations ("NI 51-102"), please be advised as follows:

1. On August 31, 2022, Harbourside CPA LLP resigned as Pharmadrug Inc.'s ("**Pharmadrug**") auditors on its own initiative.
2. On September 1, 2022, Clearhouse LLP was appointed as Pharmadrug's successor auditors.
3. The board of directors of Pharmadrug and its audit committee have approved the resignation of Harbourside CPA LLP and the appointment of Clearhouse LLP.
4. None of Harbourside CPA LLP's auditor's reports on Pharmadrug's financial statements for the most recent fiscal years ended December 31, 2021 contained a modified opinion.
5. The Board of Directors is of the opinion that there are no "reportable events" as such term is defined in section 4.11(1) of NI 51-102 which occurred in connection with the audit of the most recently completed fiscal year or for any period subsequent to the most recently completed fiscal period for which an auditors' report was issued

**PHARMADRUG INC.**

*/s/ Keith Li*

Keith Li  
Chief Financial Officer